DCB Bank

Advanced NanoTherapies (ANT) Secures $4M Strategic Investment to Accelerate Clinical Development of SirPlux Duo Drug-Coated Balloon (DCB) for Treating de novo Coronary Artery Disease (CAD)

Retrieved on: 
Tuesday, August 22, 2023
Auckland City Hospital, Cleveland Clinic, Cleveland Clinic Akron General, Structural heart disease, Restenosis, CAD, Paclitaxel, Doctor of Philosophy, De novo, DCB, Sirolimus, Interventional cardiology, MD, Patient, DCB Bank, Vascular disease, ANT, Education minister, FIH, Entrepreneurship, LOS, Coronary artery disease, Nanotechnology, Safety, Pharmaceutical industry

LOS GATOS, Calif., Aug. 22, 2023 /PRNewswire/ -- Advanced NanoTherapies Inc. (ANT), a clinical-stage medical device company committed to solving the most significant challenges in vascular disease through the creative applications of nanotechnology, today announced a $4M Series A extension from a prominent undisclosed strategic medical device company. Additionally, ANT successfully treated the first cohort of study participants in its ADVANCE-DCB first-in-human (FIH) trial, demonstrating initial short-term safety data for the next-generation SirPlux Duo Drug-Coated Balloon (DCB). The trial is evaluating the safety and performance of the SirPlux Duo DCB in de novo coronary artery disease (CAD).

Key Points: 
  • Additionally, ANT successfully treated the first cohort of study participants in its ADVANCE-DCB first-in-human (FIH) trial, demonstrating initial short-term safety data for the next-generation SirPlux Duo Drug-Coated Balloon (DCB).
  • The trial is evaluating the safety and performance of the SirPlux Duo DCB in de novo coronary artery disease (CAD).
  • "Today, we celebrate two remarkable accomplishments for ANT and SirPlux Duo DCB," said Marwan Berrada, Co-Founder and CEO of ANT.
  • "I welcome the participation of a new strategic partner as this additional investment will bolster ANT's clinical programs and accelerate the path toward U.S. IDE approval for the SirPlux Duo DCB.

Concept Medical's fourth IDE approval for the MagicTouch Sirolimus Coated Balloon is granted for the treatment of Superficial Femoral Artery Disease (SFA)

Retrieved on: 
Monday, May 29, 2023
Human leg, PTA, USFDA, RCT, PAD, Paclitaxel, ISR, Artery, Atherosclerosis, DCB, Trial of the century, Sirolimus, US, PMA, Patient, DCB Bank, Moyamoya disease, Disease, Mortality, IDE, Coronary artery disease, External carotid artery, Health, SCB, Safety, Pharmaceutical industry, Medical device, SFA

TAMPA, Fla., May 29, 2023 /PRNewswire/ -- The US FDA, on the 24th of May 2023, granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc's Sirolimus Coated Balloon (SCB) MagicTouch PTA for the treatment of Superficial Femoral Arteries (SFA).

Key Points: 
  • TAMPA, Fla., May 29, 2023 /PRNewswire/ -- The US FDA, on the 24th of May 2023, granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc's Sirolimus Coated Balloon (SCB) MagicTouch PTA for the treatment of Superficial Femoral Arteries (SFA).
  • This marks the fourth IDE approval for the Company's Sirolimus coated balloon.
  • The IDE approval will allow Concept Medical to initiate pivotal clinical study to demonstrate safety and effectiveness of the MagicTouch PTA Sirolimus coated balloon in femoral and popliteal segments.
  • MagicTouch PTA is the world's first Sirolimus coated balloon with extensive commercial usage in Europe, major markets of Asia and the Mid-Eastern markets.

Concept Medical's fourth IDE approval for the MagicTouch Sirolimus Coated Balloon is granted for the treatment of Superficial Femoral Artery Disease (SFA)

Retrieved on: 
Monday, May 29, 2023
Human leg, PTA, USFDA, RCT, PAD, Paclitaxel, ISR, Artery, Atherosclerosis, DCB, Trial of the century, Sirolimus, US, PMA, Patient, DCB Bank, Moyamoya disease, Disease, Mortality, IDE, Coronary artery disease, External carotid artery, Health, SCB, Safety, Pharmaceutical industry, Medical device, SFA

TAMPA, Fla., May 29, 2023 /PRNewswire/ -- The US FDA, on the 24th of May 2023, granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc's Sirolimus Coated Balloon (SCB) MagicTouch  PTA for the treatment of Superficial Femoral Arteries (SFA).

Key Points: 
  • TAMPA, Fla., May 29, 2023 /PRNewswire/ -- The US FDA, on the 24th of May 2023, granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc's Sirolimus Coated Balloon (SCB) MagicTouch  PTA for the treatment of Superficial Femoral Arteries (SFA).
  • This marks the fourth IDE approval for the Company's Sirolimus coated balloon.
  • The IDE approval will allow Concept Medical to initiate pivotal clinical study to demonstrate safety and effectiveness of the MagicTouch PTA Sirolimus coated balloon in femoral and popliteal segments.
  • MagicTouch PTA is the world's first Sirolimus coated balloon with extensive commercial usage in Europe, major markets of Asia and the Mid-Eastern markets.

Cardiovascular Systems, Inc. Announces First In-Human Experience With Peripheral Everolimus Drug-Coated Balloon

Retrieved on: 
Wednesday, March 9, 2022
Health, Medical Devices, Technology, Other Technology, General Health, Clinical Trials, Cardiology, NASDAQ, Safety, Heart, Cytostasis, Clinical trial, Leg, CSI, Twitter, Medtronic, Annual report, DCB Bank, Private Securities Litigation Reform Act, Physician, Plaque, Peripheral artery disease, FDA, CV, DCB, IDE, LLC, Diabetes, Stent, Medical Affairs Bureau, Testosterone and the cardiovascular system, Form 10-K, Form 10-Q, Pain, News, Acquisition, Risk, Obesity, Hospital, Prevalence, PAD, Patient, Everolimus, Coronary artery disease, COO, SEC, Male, Organization, Amputation, Walking, View, Pharmaceutical industry, MD, SFA, Covidien, CVT, Cardiovascular Systems, Inc., Chansu Vascular Technologies, LLC, Peripheral Artery Disease (PAD), CARDIOVASCULAR SYSTEMS, INC., CHANSU VASCULAR TECHNOLOGIES, LLC, PERIPHERAL ARTERY DISEASE (PAD)

The peripheral DCB was used to successfully treat a 69 year-old male with a 7.5 cm lesion in his superficial femoral artery (SFA).

Key Points: 
  • The peripheral DCB was used to successfully treat a 69 year-old male with a 7.5 cm lesion in his superficial femoral artery (SFA).
  • We believe this promising new generation of everolimus DCBs could improve patient outcomes for those suffering from peripheral artery disease.
  • Jeffery Chambers, M.D., CSIs Chief Medical Officer, said, Following the announcement of the first in-human experience with CVTs coronary everolimus DCB in November 2021, we are thrilled to announce the first in-human experience with the peripheral everolimus DCB.
  • CVT was founded by Philippe Marco, MD, with the exclusive purpose to develop peripheral and coronary DCBs using everolimus.

Cardiovascular Systems, Inc. Announces First In-Human Experience With Coronary Everolimus Drug Coated Balloon

Retrieved on: 
Thursday, November 4, 2021
Health, Medical Devices, Cardiology, Cytostasis, Calcium, Clinical trial, Artery, Plaque, Leg, ISR, Peripheral artery disease, Annual report, Acquisition, CSI, Coronary artery disease, Risk, CV, Form 10-Q, Moyamoya disease, Safety, COO, Form 10-K, CAD, Testosterone and the cardiovascular system, Medtronic, DCB Bank, PCI, Woman, Everolimus, Medical Affairs Bureau, Patient, FDA, View, Private Securities Litigation Reform Act, Organization, Heart, Degenerative disease, NASDAQ, Doctor of Philosophy, Cardiovascular disease, LLC, Twitter, SEC, Man, Atherosclerosis, Stent, Korea Disease Control and Prevention Agency, News, IDE, DCB, MACE, Hospital, Center, Death, Physician, Diabetes, Pharmaceutical industry, Medical imaging, Cardiovascular Systems, Inc., Chansu Vascular Technologies, LLC, Coronary Artery Disease (CAD), CARDIOVASCULAR SYSTEMS, INC., CHANSU VASCULAR TECHNOLOGIES, LLC, CORONARY ARTERY DISEASE (CAD)

Everolimus, the active drug in CVTs DCB formulation, acts as a cytostatic agent to reduce tissue hyperplasia and associated restenosis and has a long history of safety and efficacy in coronary drug-eluting stent applications.

Key Points: 
  • Everolimus, the active drug in CVTs DCB formulation, acts as a cytostatic agent to reduce tissue hyperplasia and associated restenosis and has a long history of safety and efficacy in coronary drug-eluting stent applications.
  • Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease.
  • CVT was founded by Philippe Marco, MD, with the exclusive purpose to develop peripheral and coronary DCBs using everolimus.
  • CSI is a registered trademark of Cardiovascular Systems, Inc. All other trademarks cited herein are owned by their respective owners.

New Round of Late-Breaking Clinical Trials Announced at VIVA21

Retrieved on: 
Wednesday, October 6, 2021
Consensus, Mortality, VIVA, CTO, Recurrence, Disrupt, SEB, Vascular disease, Freedom, Kaplan–Meier estimator, Bed, Medtronic, Blood vessel, Wynn Las Vegas, Amputation, Classification, Safety, Perforation, IVL, Chronic kidney disease, Wound healing, Multimedia, DCB Bank, Boston Scientific, DES, Brachiocephalic, Diabetes, AFS, Shock wave, Ascending limb of loop of Henle, Awareness, BMS, Observational study, Transatlantic, TASC, SEBS, PTA, EQ-5D, Atherectomy, Complex, DCB, HIV disease progression rates, Arm, Peripheral artery disease, Time Machine, Calcification, Education, Treatment, Death, Iliac, PAD, Prevalence, Research, AVF, Operational technology, Ioctl, Medical imaging, Pharmaceutical industry

Below are highlights of this morning's 4 late-breaking clinical trial presentations.

Key Points: 
  • Below are highlights of this morning's 4 late-breaking clinical trial presentations.
  • Participants were randomized to treatment with IN.PACT AV DCB (Medtronic; n = 170) or standard uncoated percutaneous transluminal angioplasty (PTA; n = 160).
  • Benefits were seen in all other subgroups, although the treatment effect was not statistically significant.
  • This is the largest randomized trial of device treatment for critical limb ischemia in this arterial segment to date.

IBEX INDIA 2020 - Diamante Blockchain Steals the Show by Winning at DCB Bank Innovation Carnival

Retrieved on: 
Tuesday, February 25, 2020
Cryptocurrencies, Computing, DCB Bank, Blockchain, Articles, DCB, Carnival, Information, Diamante

LENEXA, Kan., Feb. 25, 2020 /PRNewswire-PRWeb/ --Diamante Blockchain wins big at DCB Bank Innovation Carnival, held during the International Banking Expo IBEX INDIA 2020.

Key Points: 
  • LENEXA, Kan., Feb. 25, 2020 /PRNewswire-PRWeb/ --Diamante Blockchain wins big at DCB Bank Innovation Carnival, held during the International Banking Expo IBEX INDIA 2020.
  • This success adds Diamante Blockchain into the list of startups that will compete at the main Innovation Carnival event, scheduled for August 2020.
  • We are elated at the acknowledgment received from DCB Bank through their Innovation Carnival and look forward to the last leg of the competition in August."
  • This year marked the 8th edition of IBEX India (International Trade Fair and Conference on Banking Technology, Equipment and Services).